Share-based Payment Arrangement, Expense of Aprea Therapeutics, Inc. from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Aprea Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • Aprea Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $100,000, a 33% decline year-over-year.
  • Aprea Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2020 was $4,983,023, a 270% increase from 2019.
  • Aprea Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2019 was $1,345,722, a 308% increase from 2018.
  • Aprea Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2018 was $329,814, a 17% decline from 2017.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Aprea Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $100,000 -$49,090 -33% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $100,000 -$28,488 -22% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $100,000 $0 0% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q3 2024 $149,090 +$73,059 +96% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $128,488 -$140,835 -52% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $100,000 +$83,756 +516% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q3 2023 $76,031 +$37,795 +99% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $269,323 -$14,530,677 -98% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $16,244 -$2,083,756 -99% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q3 2022 $38,236 -$1,998,355 -98% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $14,800,000 +$12,936,502 +694% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $2,100,000 +$277,438 +15% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q3 2021 $7,154,096 $2,036,591 +$646,944 +47% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $6,507,152 $1,863,498 +$607,038 +48% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $5,900,114 $1,822,562 +$917,091 +101% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $4,983,023 $1,431,445 +$616,857 +76% 01 Oct 2020 31 Dec 2020 10-K 16 Mar 2021 2020 FY
Q3 2020 $4,366,166 $1,389,647 +$1,143,422 +464% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $3,222,744 $1,256,460 +$1,069,497 +572% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $2,153,247 $905,471 +$807,525 +824% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $1,345,722 $814,588 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
Q3 2019 $246,225 +$166,434 +209% 01 Jul 2019 30 Sep 2019 10-Q 06 Nov 2020 2020 Q3
Q2 2019 $186,963 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $97,946 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020 2020 Q1
Q3 2018 $79,791 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2019 2019 Q3

Aprea Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2020 $4,983,023 +$3,637,301 +270% 01 Jan 2020 31 Dec 2020 10-K 16 Mar 2021 2020 FY
2019 $1,345,722 +$1,015,908 +308% 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
2018 $329,814 -$65,626 -17% 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2021 2020 FY
2017 $395,440 01 Jan 2017 31 Dec 2017 10-K 27 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.